Adimab In Discovery Pacts with Biogen, Novo Nordisk

Adimab has entered separate discovery collaborations with Biogen Idec and Novo Nordisk. Adimab will use its platform to identify fully human antibodies against two targets selected by Biogen and two from Novo Nordisk. Both Biogen and Novo Nordisk have the option to commercialize antibodies generated from the collaborations. Adimab will receive upfront payments and preclinical milestones from both companies, and is eligible to receive clinical development milestones and royalties on sales. Financial terms were not disclosed.

“Adimab is increasingly recognized as the premier antibody discovery technology in the industry,” said Tillman Gerngross, Adimab’s chief executive officer and co-founder. “Our partners are looking for technologies that improve the lead discovery process and enhance their ability to quickly move novel antibodies into the clinic. Our technology is simply faster, dramatically reduces the risk of development failures, and generates higher quality leads even against challenging targets; in fact many of our partners come to us with targets that have failed using traditional phage display approaches.”